New 384-well plates format for BIOMIMESYS® Liver & Oncology entitling Cell-Based Assays High-Throughput Screening

HCS-Pharma is pleased to launch BIOMIMESYS® Liver and Oncology in ready-to-use 384-well plate format for screening applications. Adopt BIOMIMESYS® 3D cell culture systems and obtain more predictive in vitro models. You can find our presentations in PDF format for BIOMIMESYS® Liver https://www.hcs-pharma.biz/share/public/hcspharma-flyer-biomimesys-liverv0 for BIOMIMESYS® Oncology https://www.hcs-pharma.biz/share/public/hcspharma-flyer-biomimesys-oncologyv0 For more information, contact Read more…

Biomimesys meets Stem cells: presentations at FSSCR event and “From 3D Culture to Organoid” symposium

Biomimesys is providing a great opportunity to culture human induced pluripotent stem cells (hiPSCs) in 3D and differentiate them into different kind of cell types including liver cells. Showcased by Méryl Roudaut at the 20th International Congress on In Vitro Toxicology (ESTIV2018), our co-development with the institute du thorax (U1087) Read more…

Poster – Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotypic screening – Application on metabolic diseases – version DHU2020

Ask for high quality link by putting your email below We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in Read more…